Bantam Pharmaceutical
Pharmaceuticals, 505 Park Ave, Durham, North Carolina, 10022, United States, 1-10 Employees
Phone Number: 64********
Who is BANTAM PHARMACEUTICAL
Bantam Pharmaceutical is a drug discovery company harnessing the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial dynamics, ...
Read More
-
Headquarters: 505 Park Ave, Durham, North Carolina, 10022, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from BANTAM PHARMACEUTICAL
Bantam Pharmaceutical Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Bantam Pharmaceutical
Answer: Bantam Pharmaceutical's headquarters are located at 505 Park Ave, Durham, North Carolina, 10022, United States
Answer: Bantam Pharmaceutical's phone number is 64********
Answer: Bantam Pharmaceutical's official website is https://bantampharma.com
Answer: Bantam Pharmaceutical's revenue is $1 Million to $5 Million
Answer: Bantam Pharmaceutical's SIC: 2834
Answer: Bantam Pharmaceutical has 1-10 employees
Answer: Bantam Pharmaceutical is in Pharmaceuticals
Answer: Bantam Pharmaceutical contact info: Phone number: 64******** Website: https://bantampharma.com
Answer: Bantam Pharmaceutical is a drug discovery company harnessing the power of mitochondrial dynamics to address unmet needs in oncology. Using its unique expertise in mitochondrial dynamics, Bantam is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. Bantam is currently pursuing an IND application for Its lead candidate, BTM-3566, in B-cell malignancies. About BTM-3566 BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566s anti-cancer mechanism of action is unique from any other therapeutic, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is currently underway and will be completed by Q1 2022.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month